P
Protalix BioTherapeutics, Inc. (PLX)
ASE – Real Time Price. Currency in USD
1.91
-0.03 (-1.55%)
At close: May 12, 2026, 4:00 PM EDT
2.02
+0.12 (6.28%)
Pre-market: May 13, 2026, 7:19 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
1.91
-0.03 (-1.55%)
At close: May 12, 2026, 4:00 PM EDT
2.02
+0.12 (6.28%)
Pre-market: May 13, 2026, 7:19 AM EDT
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
| Name | Position |
|---|---|
| Mr. Dror Bashan | President, CEO & Director |
| Mr. Gilad Mamlok | Senior VP, CFO Treasurer & Secretary |
| Mr. Yaron Naos B.Sc., MBA | SVP & COO |
| Ms. Yael Fellous | Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | DEF 14A | plx-20260625xdef14a.htm |
| 2026-03-18 | 8-K | plx-20260318x8k.htm |
| 2026-03-09 | 8-K | plx-20260309x8k.htm |
| 2026-02-11 | 8-K | plx-20260211x8k.htm |
| 2026-01-30 | 8-K | tm264565d1_8k.htm |
| 2026-01-05 | 8-K | plx-20260105x8k.htm |
| 2025-11-13 | 8-K | plx-20251113x8k.htm |
| 2025-11-03 | 8-K | plx-20251103x8k.htm |
| 2025-10-17 | 8-K | plx-20251017x8k.htm |
| 2025-08-22 | 8-K | tm2524070d1_8k.htm |